1. Medicines
  2. Respiratory and Inflammation
  3. ENERZAIR® BREEZHALER® (indacaterol acetate/glycopyrronium bromide/mometasone furoate inhalation powder)
  4. The inhaler device

Prescribing information

 

The inhaler device

       

The BREEZHALER device provides confidence that the full dose has been taken

 

The BREEZHALER® device provides certainty that the full dose has been taken

Image of couple taking selfie giving thumbs up next to image of Enerzair inhaler

Icon of tick for correct use

Per cent values represent proportion of patients who supplied a response.

Icon of tick for correct use

 

How to use the BREEZHALER device

Watch the following video to learn how to use the BREEZHALER.

Unlock the potential of inhaled asthma care with ENERZAIR® BREEZHALER (indacaterol acetate/glycopyrronium bromide/mometasone furoate inhalation powder)

With once-daily ENERZAIR BREEZHALER,1 your patients can live and breathe every moment.

 

ENERZAIR® BREEZHALER® is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long-acting beta2-agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.1

*Data derived from studies in COPD patients using available treatments for COPD in the BREEZHALER devices.2,3
†Compared to Accuhaler®, Respimat® and Turbohaler®.2
‡Errors were considered critical if they could have substantially affected dose delivery to the lung.2
§ENERZAIR® BREEZHALER® (indacaterol acetate/glycopyrronium bromide/mometasone furoate inhalation powder) is not licensed for treatment of COPD.1
Compared to Ellipta® and HandiHaler®.3
**From a randomised, open-label multicentre, crossover, phase IV study, designed to compare the peak inspiratory flow rate values generated by patients with moderate to very severe airflow obstruction through the BREEZHALER, Ellipta® and HandiHaler® dry powder inhalers.3
††96 pharmacies collected data from 570 adult asthma patients in Australia. Of these, 348 patients were taking preventer/combination medication on a regular basis and were included. All patients who demonstrated incorrect technique at visit 1 were trained to mastery. Of these, data were available for 238 at follow-up visit.4

HandiHaler® and Respimat® are registered trademarks of Boehringer Ingelheim. Ellipta® and Accuhaler® are registered trademarks of GlaxoSmithKline. Turbohaler® is a registered trademark of AstraZeneca.

Indication: ENERZAIR BREEZHALER is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long-acting beta2-agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.1

COPD, chronic obstructive pulmonary disease.

References

  1. ENERZAIR BREEZHALER Summary of Product Characteristics
  2. Molimard M et al. Eur Respir J 2017;49:1601794.
  3. Altman P et al. BMC Pulm Med 2018;18:100.
  4. Azzi E et al. NPJ Prim Care Respir Med 2017;27:29.
ENE20-C005 November 2020.
Respiratory and Inflammation
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at http://www.report.novartis.com/
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]